Soleno Therapeutics Inc [NASDAQ: SLNO] closed the trading session at $67.39.
The stocks have a year to date performance of 49.92 percent and weekly performance of 39.24 percent. The stock has been moved at 43.75 percent over the last six months. The stock has performed 49.42 percent around the most recent 30 days and changed 49.94 percent over the most recent 3-months.
If compared to the average trading volume of 578.78K shares, SLNO reached to a volume of 15183879 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Soleno Therapeutics Inc [SLNO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SLNO shares is $96.44 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SLNO stock is a recommendation set at 1.11. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Stifel have made an estimate for Soleno Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on March 05, 2025. While these analysts kept the previous recommendation, Stifel raised their target price to Buy. The new note on the price target was released on December 02, 2024, representing the official price target for Soleno Therapeutics Inc stock. Previously, the target price had yet another raise to $72, while Robert W. Baird analysts kept a Outperform rating on SLNO stock.
The Average True Range (ATR) for Soleno Therapeutics Inc is set at 3.90 The Price to Book ratio for the last quarter was 12.57, with the Price to Cash per share for the same quarter was set at 6.36.
SLNO stock trade performance evaluation
Soleno Therapeutics Inc [SLNO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 39.24. With this latest performance, SLNO shares gained by 49.42% in over the last four-week period, additionally plugging by 43.75% over the last 6 months – not to mention a rise of 61.72% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SLNO stock in for the last two-week period is set at 81.90, with the RSI for the last a single of trading hit 87.58, and the three-weeks RSI is set at 76.60 for Soleno Therapeutics Inc [SLNO]. The present Moving Average for the last 50 days of trading for this stock 48.41, while it was recorded at 53.13 for the last single week of trading, and 48.76 for the last 200 days.
Soleno Therapeutics Inc [SLNO]: An insightful look at the core fundamentals
Soleno Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 15.68 and a Current Ratio set at 15.68.
Soleno Therapeutics Inc [SLNO]: Institutional Ownership
There are presently around $113.72%, or 117.16%% of SLNO stock, in the hands of institutional investors. The top three institutional holders of SLNO stocks are: VIVO CAPITAL, LLC with ownership of 7.32 million shares, which is approximately 18.9401%. CARLYLE GROUP INC., holding 4.07 million shares of the stock with an approximate value of $$166.36 million in SLNO stocks shares; and CARLYLE GROUP INC., currently with $$137.14 million in SLNO stock with ownership which is approximately 8.6946%.
